Rainbow Children's Medicare (RAINBOW) investor relations material

Executive summary

• Achieved 12% year-over-year revenue growth in Q3 FY26, reaching ₹4,454 million, with PAT up 7% to ₹739 million and EBITDA up 9% to ₹1,470 million.

• Operational expansion included new hospitals in Warangal, Guwahati, and Rajahmundry, increasing total bed capacity to 2,375 across 23 hospitals in 9 cities.

• Leadership strengthened with the appointment of Mr. Abrar Ali Dalal as CEO and other senior hires to drive growth and operational efficiency.

• Unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025 were reviewed and approved by the Board on 28 January 2026.

• Statutory auditors issued unmodified (clean) limited review reports for both standalone and consolidated results.

Financial highlights

• Q3 FY26 consolidated revenue was ₹4,454.48 million, up 12% year-over-year; PAT at ₹738.97 million, up 7%; EBITDA at ₹1,470 million, up 9%.

• Nine-month FY26 consolidated revenue was ₹12,431.76 million, up 9% year-over-year; PAT at ₹2,033.26 million, up 8%; EBITDA at ₹3,995 million, up 6%.

• Q3 EBITDA margin at 33%; nine-month EBITDA margin at 32.1%.

• ARPOB for Q3 FY26 was ₹58,362 (+9% YoY); 9M FY26: ₹59,324 (+12% YoY).

• Cash position of INR 579 crore as of Dec 31, 2025, supporting ongoing capex and M&A plans.

Outlook and guidance

• Targeting occupancy improvement to 55-60% in the next year through aggressive sales, marketing, and potential CGHS empanelment.

• Expansion plans include new hospitals in Hennur, Coimbatore, Gurugram, and Pune, targeting a total bed capacity of 3,165 by FY28-29.

• Maintaining medium-term revenue CAGR guidance of 18%.

• Digital initiatives and specialty expansion (e.g., liver transplants) to drive future growth.

• The company continues to monitor regulatory changes, including new labour codes, and will adjust accounting as needed.